TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1318364

Group type: EXPERIMENTAL
Intervention: Foscarnet (200 mg/kg continuous infusion prior to 1988 or 60 mg/kg t.i.d. or 90 mg/kg b.i.d. intermittent infusion with saline hyperhydration)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Foscarnet
Number of subjects: 66
Study: 6147838

Group type: EXPERIMENTAL
Intervention: lormetazepam (1.5 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: flurazepam (30 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: temazepam (30 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: active drug conditions (lormetazepam, flurazepam, temazepam)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: lormetazepam
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: temazepam
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: active drugs
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: flurazepam
Number of subjects: 16
Study: 29743078

Group type: EXPERIMENTAL
Intervention: MIV‐711 (single oral doses from 20 to 600 mg in humans; 3‐30 µmol/kg in monkeys)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: MIV‐711 (repeat oral dosing)
Number of subjects: 2
Study: 27916408

Group type: EXPERIMENTAL
Intervention: SA4Ag vaccine
Number of subjects: 454

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 454
Study: 25117063

Group type: EXPERIMENTAL
Intervention: Overweight target
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Uncontrollability (medical) information
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Average-weight target
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Participant body image state
Number of subjects: 185
Study: 24067387

Group type: EXPERIMENTAL
Intervention: Multivitamin with guaraná
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Multivitamin without guaraná
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 21239190

Group type: EXPERIMENTAL
Intervention: AS195 (red-vine-leaf extract) 720 mg per day for 12 weeks
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: AS195 (red-vine-leaf extract)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 248
Study: 18496349

Group type: EXPERIMENTAL
Intervention: SpineCor (flexible spinal orthosis)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Rigid spinal orthosis
Number of subjects: 43
Study: 17063001

Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 12728086

Group type: EXPERIMENTAL
Intervention: 3-component acellular pertussis vaccine administered at birth (group 1)
Number of subjects: 91

Group type: COMPARATOR
Intervention: 3-component acellular pertussis vaccine administered at 3, 5, and 11 months (group 2)
Number of subjects: 91
Study: 10992828

Group type: EXPERIMENTAL
Intervention: Intravenous ketoprofen 1 mg kg‐1
Number of subjects: 100

Group type: COMPARATOR
Intervention: Oral ketoprofen 1 mg kg‐1
Number of subjects: 100

Group type: COMPARATOR
Intervention: Both oral and i.v. placebo
Number of subjects: 100
Study: 8776645

Group type: EXPERIMENTAL
Intervention: Group 1 (autologous fresh blood donated before bypass, cell saver and membrane oxygenator used)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Group 2 (reinfused with autologous blood only)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Group 3 (control group, blood remaining in the oxygenator reinfused)
Number of subjects: 150
Study: 1727903

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMZ)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study: 6384070

Group type: EXPERIMENTAL
Intervention: bepridil hydrochloride
Number of subjects: 13
Study: 31399460

Group type: EXPERIMENTAL
Intervention: Daily observed treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment dispensed every 2 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment dispensed every 2 weeks with adherence psychological intervention
Number of subjects: 0
Study: 28787749

Group type: EXPERIMENTAL
Intervention: Labor scale
Number of subjects: 110

Group type: COMPARATOR
Intervention: WHO partograph
Number of subjects: 110
Study: 25477225

Group type: EXPERIMENTAL
Intervention: Hyperdense artery sign (HAS) on noncontrast CT
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Proximal arteries
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Distal arteries
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Thinner CT slices
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Absence of HAS
Number of subjects: 273
Study: 24418726

Group type: EXPERIMENTAL
Intervention: Acetazolamide (500 mg intravenously, acute)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Acetazolamide (2 g orally, prolonged)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Inhaled CO2 (1%-2%) during exercise
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Prolonged acetazolamide at rest
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Maximum exercise after prolonged acetazolamide
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Overnight apnea/hypopnea index
Number of subjects: 20
Study: 22851561

Group type: COMPARATOR
Intervention: Standard (conventional) fractionated radiotherapy (STRT) followed by chemotherapy
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiotherapy (HFRT) followed by chemotherapy
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Both treatment arms (HFRT and STRT)
Number of subjects: 340
Study: 19220307

Group type: EXPERIMENTAL
Intervention: Sumatriptan/Naproxen Sodium 85/500 mg (S/NS)
Number of subjects: 570

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 570
Study: 18077942

Group type: EXPERIMENTAL
Intervention: New hypodense lesion on the first postoperative day CT
Number of subjects: 156

Group type: COMPARATOR
Intervention: No lesions on any follow-up CT scans
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Lesion appearing later than the first postoperative morning
Number of subjects: 156
Study: 15683159

Group type: EXPERIMENTAL
Intervention: Combined hepatitis A and hepatitis B vaccine
Number of subjects: 304

Group type: COMPARATOR
Intervention: Monovalent hepatitis A and hepatitis B vaccine
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 304
Study: 11386781

Group type: EXPERIMENTAL
Intervention: Moulded metacarpal brace
Number of subjects: 73

Group type: COMPARATOR
Intervention: Neighbour strapping
Number of subjects: 73
Study: 9702948

Group type: EXPERIMENTAL
Intervention: Clodronate
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 8994122

Group type: COMPARATOR
Intervention: High CSF lactate levels in MS patients during clinical exacerbation of relapsing‐remitting course
Number of subjects: 52

Group type: COMPARATOR
Intervention: CSF lactate in MS patients with MRI evidence of Gd‐enhanced plaques
Number of subjects: 52

Group type: COMPARATOR
Intervention: CSF lactate positivity in MS patients with clinical activity
Number of subjects: 52

Group type: COMPARATOR
Intervention: CSF lactate positivity in MS patients with MRI enhancement
Number of subjects: 52

Group type: COMPARATOR
Intervention: Elevated lactate signal in Gd‐enhanced plaques
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Increased CSF lactate in patients with acute meningitis and idiopathic polyneuropathy
Number of subjects: 52

Group type: COMPARATOR
Intervention: Decrease of CSF formulate levels in MS patients during active and inactive clinical phase
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Significant increase of choline in acute plaques
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Decrease of N‐acetyl aspartate in chronic plaques
Number of subjects: 52

Group type: COMPARATOR
Intervention: CSF glucose levels in bacterial meningitis
Number of subjects: 52
Study: 2126437

Group type: EXPERIMENTAL
Intervention: Pravastatin 5 mg
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Pravastatin 10 mg
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Pravastatin (all doses)
Number of subjects: 306

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 306
Study: 7211425

Group type: EXPERIMENTAL
Intervention: Pimozide (1 to 2.6 mg per day)
Number of subjects: 10
Study: 31958166

Group type: COMPARATOR
Intervention: Freehand surgery
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Fully guided surgery
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Pilot, partial, and full guided surgery protocols
Number of subjects: 101
Study: 31640993

Group type: EXPERIMENTAL
Intervention: TiM telehealth plus usual care
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 40
Study: 26765160

Group type: EXPERIMENTAL
Intervention: Warm compress bistage intervention
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control (routine care)
Number of subjects: 150
Study: 23893418

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injection
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (saline solution) injection
Number of subjects: 40
Study: 21880992

Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 177
Study: 19552748

Group type: EXPERIMENTAL
Intervention: Verapamil (80 mg three times daily for 6 days)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control phase (fexofenadine alone)
Number of subjects: 13
Study: 16735920

Group type: EXPERIMENTAL
Intervention: Hypertonic Dead Sea salt (DSS) solution
Number of subjects: 42

Group type: COMPARATOR
Intervention: Hypertonic saline
Number of subjects: 42
Study: 15025782

Group type: COMPARATOR
Intervention: Placebo (in addition to usual standard of care)
Number of subjects: 1690
Study: 11370224

Group type: EXPERIMENTAL
Intervention: Quadruple therapy (PPI + three antibiotics)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Triple therapy (PPI + two antibiotics)
Number of subjects: 0
Study: 9336372

Group type: EXPERIMENTAL
Intervention: Concentric remodeling patients
Number of subjects: 118
Study: 8227112

Group type: EXPERIMENTAL
Intervention: Oral mesoglycan (200 mg/day)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 2
Study: 3801953

Group type: EXPERIMENTAL
Intervention: Metoclopramide plus dexamethasone
Number of subjects: 36

Group type: COMPARATOR
Intervention: Metoclopramide alone
Number of subjects: 36

Group type: COMPARATOR
Intervention: Metoclopramide
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Metoclopramide and Metoclopramide plus dexamethasone
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Combination antiemetic therapy
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Late nausea or vomiting
Number of subjects: 36
Study: 31861922

Group type: EXPERIMENTAL
Intervention: Public hospitals
Number of subjects: 154

Group type: COMPARATOR
Intervention: Private hospitals
Number of subjects: 154
Study: 30028029

Group type: EXPERIMENTAL
Intervention: Radiofrequency (RF) ablation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Comparison between RF and Cryoballoon groups
Number of subjects: 30
Study: 27654572

Group type: EXPERIMENTAL
Intervention: Therapeutic tape
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sham tape
Number of subjects: 15

Group type: COMPARATOR
Intervention: No tape
Number of subjects: 15
Study: 25046948

Group type: EXPERIMENTAL
Intervention: Wuling Capsule (WC), 0.33 g each pill, 3 pills per day, three times per day
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo, 3 pills per day, three times per day
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Wuling Capsule (WC)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 22892226

Group type: EXPERIMENTAL
Intervention: School-based physical activity intervention
Number of subjects: 176

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 176
Study: 19717327

Group type: EXPERIMENTAL
Intervention: Conservative therapy
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Fear of movement
Number of subjects: 146
Study: 17880761

Group type: EXPERIMENTAL
Intervention: IL-15 treatment in vitro
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Controller group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-Controller group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IL-15 levels
Number of subjects: 0
Study: 16213850

Group type: EXPERIMENTAL
Intervention: Ovarian biopsy in 10 women
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Women with histologically confirmed autoimmune oophoritis
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Overall testing for adrenal cortex autoantibodies
Number of subjects: 266
Study: 11837554

Group type: EXPERIMENTAL
Intervention: BMS‐284756 (400 mg) after a high-fat meal
Number of subjects: 14

Group type: COMPARATOR
Intervention: BMS‐284756 (400 mg) in a fasted state
Number of subjects: 14
Study: 10419911

Group type: EXPERIMENTAL
Intervention: Nurse endoscopists
Number of subjects: 328

Group type: COMPARATOR
Intervention: Gastroenterologists
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 328
Study: 7587260

Group type: EXPERIMENTAL
Intervention: Combination of preoperative, intraoperative, and postoperative variables (including Parsonnet score, APACHE II and III scores)
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Logistic regression model including bypass time, need for inotropes, mean arterial pressure, urea, and Glasgow Coma Scale
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Parsonnet score
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: APACHE II risk of dying
Number of subjects: 1008
Study: 1775733

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Pizotifen 0.5 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Metergoline 6 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Methysergide 2 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Metoclopramide alone
Number of subjects: 6
Study: 6133757

Group type: COMPARATOR
Intervention: 0.6 mg LH-RH daily for 4 weeks (placebo-controlled)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 1.2 mg LH-RH daily for 4 weeks (open study)
Number of subjects: 50
Study: 31349092

Group type: EXPERIMENTAL
Intervention: Isokinetic eccentric training (IG)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Conventional eccentric training (CG)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Single leg hop test
Number of subjects: 32
Study: 28233071

Group type: EXPERIMENTAL
Intervention: Active laser group (ALG) received pulsed high-intensity laser therapy (HILT) three times per week for 6 weeks, along with 10 mg cetirizine tablets twice daily and 10 mg at bedtime.
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Active laser group (ALG) received HILT and cetirizine.
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo laser group (PLG) received placebo HILT and cetirizine.
Number of subjects: 49
Study: 26480969

Group type: EXPERIMENTAL
Intervention: Higher glycemic index (GI)
Number of subjects: 6606

Group type: EXPERIMENTAL
Intervention: Higher glycemic load (GL)
Number of subjects: 6606

Group type: EXPERIMENTAL
Intervention: Changes in dietary GI
Number of subjects: 6606

Group type: EXPERIMENTAL
Intervention: Changes in dietary GL
Number of subjects: 6606
Study: 23571799

Group type: EXPERIMENTAL
Intervention: Electrical sternum lifting system (ESLS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mechanical sternum lifting device
Number of subjects: 0
Study: 21233475

Group type: EXPERIMENTAL
Intervention: HDP cohort
Number of subjects: 1092

Group type: EXPERIMENTAL
Intervention: Preterm delivery in HDP cohort
Number of subjects: 1092

Group type: EXPERIMENTAL
Intervention: HDP cohort aged 15 to 18 years
Number of subjects: 1092

Group type: EXPERIMENTAL
Intervention: HDP cohort aged 35 years and older
Number of subjects: 1092

Group type: COMPARATOR
Intervention: Non-HDP cohort
Number of subjects: 1092
Study: 19297566

Group type: EXPERIMENTAL
Intervention: PSA screening offered at an average of once every 4 years
Number of subjects: 182000

Group type: COMPARATOR
Intervention: Control group (no PSA screening)
Number of subjects: 182000

Group type: EXPERIMENTAL
Intervention: PSA screening
Number of subjects: 182000

Group type: EXPERIMENTAL
Intervention: PSA screening (actual screened men)
Number of subjects: 182000
Study: 17577323

Group type: EXPERIMENTAL
Intervention: Lactobacillus brevis-containing lozenges
Number of subjects: 29
Study: 15631350

Group type: EXPERIMENTAL
Intervention: Non-operative treatment (n = 31)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Surgical treatment (n = 33)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (n = 20)
Number of subjects: 64
Study: 11294772

Group type: EXPERIMENTAL
Intervention: Ghrelin (10 microg/kg, intravenous bolus)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 9542481

Group type: EXPERIMENTAL
Intervention: Oral acetaminophen (1000 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 7760586

Group type: EXPERIMENTAL
Intervention: Flunarizine (5 mg twice-daily for 1 month, then 5 mg once-daily for 2 months)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo (matching capsule)
Number of subjects: 42
Study: 3417354

Group type: EXPERIMENTAL
Intervention: Ty21a
Number of subjects: 30

Group type: COMPARATOR
Intervention: TAB
Number of subjects: 30
Study: 30998929

Group type: EXPERIMENTAL
Intervention: Facebook advertisements designed to increase knowledge of the efficacy, ease of use and safety of LARC
Number of subjects: 152743

Group type: COMPARATOR
Intervention: Control group (no advertisements)
Number of subjects: 152743

Group type: EXPERIMENTAL
Intervention: Facebook advertisements
Number of subjects: 152743
Study: 28049964

Group type: EXPERIMENTAL
Intervention: Nonsurgical periodontal treatment (NSPT)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 62
Study: 26666301

Group type: EXPERIMENTAL
Intervention: Systematic early integration of palliative care in standard oncology care
Number of subjects: 182

Group type: COMPARATOR
Intervention: Standard oncology care alone
Number of subjects: 182
Study: 23669294

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (5 mg intravenous infusion per year)
Number of subjects: 483

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 483
Study: 21985895

Group type: EXPERIMENTAL
Intervention: Toothpaste M (containing stannous fluoride)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Toothpaste PE (containing stannous fluoride)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control toothpaste (containing sodium fluoride)
Number of subjects: 12
Study: 18505546

Group type: EXPERIMENTAL
Intervention: Acute submaximal exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hypertensive patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patients with CAD
Number of subjects: 0
Study: 16406221

Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol (50 microg four times with 4 h intervals)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Oxytocin infusion (starting from 2 mIU/min, increased every 30 min up to 40 mIU/min)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol
Number of subjects: 100

Group type: COMPARATOR
Intervention: Oxytocin infusion
Number of subjects: 100
Study: 12553389

Group type: EXPERIMENTAL
Intervention: Oral ketamine 8 mg kg(‐1)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Oral ketamine 4 mg kg(‐1)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Oral ketamine 6 mg kg(‐1)
Number of subjects: 80
Study: 10845311

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 347

Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 347
Study: 8648018

Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chlorpheniramine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Terfenadine
Number of subjects: 0
Study: 1739573

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium suppositories 150‐200 mg day‐1
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 6746191

Group type: EXPERIMENTAL
Intervention: Energy-reduced diet (1370 kcal, 5.7 MJ) with 24 energy per cent carbohydrates
Number of subjects: 23

Group type: COMPARATOR
Intervention: Isocaloric diet (1400 kcal, 5.8 MJ) with 59 energy per cent carbohydrates (mainly mono- and disaccharides)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Both groups (Gp I and Gp II)
Number of subjects: 23
Study: 31536786

Group type: EXPERIMENTAL
Intervention: Radiofrequency (RF) denervation and an exercise programme
Number of subjects: 1148
Study: 27689315

Group type: EXPERIMENTAL
Intervention: First You Should Get Stronger program
Number of subjects: 40
Study: 27421884

Group type: EXPERIMENTAL
Intervention: SystemCHANGE™ intervention for 6 months
Number of subjects: 190

Group type: COMPARATOR
Intervention: Attention-control group for 6 months
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: SystemCHANGE™ intervention
Number of subjects: 190

Group type: COMPARATOR
Intervention: Attention-control group
Number of subjects: 190
Study: 24740822

Group type: EXPERIMENTAL
Intervention: Intraarticular sprifermin (10 μg, 30 μg, 100 μg)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study: 22677328

Group type: EXPERIMENTAL
Intervention: Open surgical procedure
Number of subjects: 71

Group type: COMPARATOR
Intervention: Closed surgical procedure
Number of subjects: 71
Study: 20586935

Group type: EXPERIMENTAL
Intervention: lamivudine
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control (no virological response)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: interferon‐alpha2b
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: sequential therapy of lamivudine‐interferon‐alpha2b
Number of subjects: 71
Study: 17573292

Group type: EXPERIMENTAL
Intervention: Techniques to enhance recruitment and retention in RCTs for cancer symptom management
Number of subjects: 0
Study: 15817970

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Gelatin polymer (Haemaccel)
Number of subjects: 60